Indeed, a combination study of SRA737 with low-dose gemcitabine including expansion cohorts of patients with tumours harbouring selected genetic alterations hypothesized to confer sensitivity to Chk1 inhibition has been completed (NCT02797977). This evidence concerns the gene CHEK1 and neoplasm.